Zealand hosts conference call on August 16 at 4 pm CET/10 am EDT to present first half of 2018 results
Press Release - No. 18 / 2018Zealand hosts conference call on August 16 at 4 pm CET/10 am EDT to present first half of 2018 results
Copenhagen, August 13, 2018 - Zealand Pharma A/S ("Zealand") (CVR no. 20 04 50 78) announces that it will be hosting a conference call on August 16, 2018 at 4 pm CET/10 am EDT following the announcement of its H1 2018 results.
Participating in the call will be President and Chief Executive Officer Britt Meelby Jensen, Executive Vice President and Chief Financial Officer Mats Blom and Executive Vice President and Chief Medical and Development Officer Adam Steensberg. The presentation will be followed by a Q&A session. The conference call will be conducted in English, and the dial-in numbers are:
Denmark........................ +45 35 15 81 21
United Kingdom: ........... +44 (0)330 336 9411
United States: ............... +1 929 477 0324
A live audio webcast of the call, including an accompanying slide presentation, will be available via the following link, https://edge.media-server.com/m6/p/2jzj5h4j, and also will be accessible on the Investor section of Zealand's website ( www.zealandpharma.com ). Participants are advised to register for the webcast approximately 10 minutes before the scheduled start. A recording of the event and a transcript will be available on the Investor section of Zealand's website after the call.
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, e-mail: firstname.lastname@example.org
Mats Blom, Executive Vice President, Chief Financial Officer
Tel: +45 31 53 79 73, e-mail: email@example.com
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a late-stage clinical portfolio of proprietary product candidates focusing on specialty gastrointestinal and metabolic diseases. In addition, it has two marketed products, commercialized by Sanofi, and two product candidates under license collaboration with Boehringer Ingelheim.
Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow Zealand on LinkedIn or Twitter @ZealandPharma.18-18_0813- H12018 Conference call
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Zealand Pharma via GlobeNewswire